Company
Nionyx Bio
Nionyx Bio, a precision focused gene therapy company developing a proprietary AAV capsid platform and pipeline for renal diseases
Also known as Nionyx Bio, Inc
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- Nionyx Bio, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Nionyx Bio is redefining gene therapy for the kidney. Its proprietary AAV capsid platform is designed to deliver one-time, tissue-targeted therapies with improved safety, precision, and scalability. Backed by top-tier investors and led by a team of gene therapy pioneers, Nionyx is building the AAV Kidney Atlas to de-risk development and accelerate a new class of renal gene therapies.
Funding snapshot
- Total raised
- $4MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Seed, $4M2025-09-29
Funding rounds
- Seed
- $4M2025-09-29, Company stated
Loading relationship preview